Skip to main content
. 2020 May 19;57(2):433–444. doi: 10.3892/ijo.2020.5067

Figure 7.

Figure 7

(A) In vivo antitumor efficiencies of different treatment strategies against K-7 tumor-bearing mice (n=5). (B) Body weight changes. (C) Images of excised tumors. (D) Necrosis percentage of tumor tissues evaluated by hematoxylin and eosin staining (n=3). *P<0.05; **P<0.01; ***P<0.001. CD-CUR, β-cyclodextrin curcumin; DOX, doxorubicin.